Zainab Taleb is affiliated with the University of Windsor, contributing to research in circadian biology and its implications for digestive health. Her work focuses on the interplay between circadian rhythms, intestinal stem cells, and disease mechanisms such as colitis and tumor initiation. She participated in a university panel addressing vaccine hesitancy related to the pandemic response. Research emphasizes circadian clock genes like BMAL1 and their role in metabolic and inflammatory processes. Collaborations may involve interdisciplinary teams studying chronobiology's impact on gastrointestinal disorders and oncology. Her studies utilize animal models to investigate timing-dependent physiological responses, with potential applications in therapeutic timing strategies.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Andrew Spakowitz is a Professor of Chemical Engineering, Materials Science and Engineering, and by courtesy, Applied Physics and Chemistry at Stanford University. He currently serves as the Senior Associate Dean for Research and Faculty Affairs and holds the Tang Family Foundation Chair of the Department of Chemical Engineering. His academic career at Stanford spans from Assistant Professor (2006-2014) to Associate Professor (2014-2020) and now Professor since 2020. Dr. Spakowitz earned his PhD in 2004, MS in 2001 from the California Institute of Technology, and his BS in Chemical Engineering from the University of Wisconsin, Madison in 1999. He completed postdoctoral training in Molecular and Cell Biology and Biophysics at UC Berkeley from 2004-2006. His research focuses on theoretical and computational approaches to understanding biological processes and complex materials. The Spakowitz lab addresses fundamental chemical and physical phenomena through four main research themes: chromosomal organization and dynamics, protein self-assembly, polymer membranes, and charge transport in conducting polymers. His group employs diverse theoretical and computational methods including analytical theory of semiflexible polymers, polymer field theory, continuum elastic mechanics, Brownian dynamics simulation, equilibrium and dynamic Monte Carlo simulations, and reaction-diffusion modeling. Analysis of his recent publications reveals a strong emphasis on epigenetics and chromatin dynamics, with significant work on DNA methylation patterns, nucleosome clustering, and chromosome organization. His research also extends to polymer physics applications in biological systems, particularly in respiratory diseases, water purification membranes, and bacterial phage interactions with human mucus. Tang Family Foundation Chair of the Department of Chemical Engineering Professor Spakowitz mentors several graduate students and postdoctoral scholars in the Chemical Engineering and Materials Science departments. His lab members work on diverse projects spanning from chromatin dynamics to polymer membranes for water purification. He teaches multiple courses including CHEMENG 120B (Energy and Mass Transport), CHEMENG 340 (Molecular Thermodynamics), CHEMENG 466 (Polymer Physics), and CHEMENG 467 (Physics of Biomacromolecules). The Spakowitz lab operates from Clark S295 at Stanford University, conducting theoretical and computational research that bridges chemistry, physics, biology, and engineering disciplines to address complex problems across multiple length and time scales.
Prof. Dr. Helmuth Gehart is a faculty member at the Institute of Molecular Health Sciences , ETH Zurich . He leads the Tumor and Stem Cell Dynamics research group, focusing on dynamic cell identity in regeneration and cancer. Research Interests : Stem cell-environment interactions, organoid technology, single-cell sequencing, and mechanisms of tissue repair/tumorigenesis. Publications : 10+ articles (2015-2024) on organoid models, stem cell dynamics, and cancer biology.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Zhe Ji is an Assistant Professor in the Department of Biomedical Engineering at McCormick School of Engineering and the Department of Pharmacology at Feinberg School of Medicine, Northwestern University. His research integrates computational and experimental genomics to study gene transcription and RNA translation in cell fate commitment and oncogenic processes, aiming to develop precision medicine strategies. **Education**: Postdoctoral Fellow in Cancer Systems Biology, Harvard Medical School Postdoctoral Fellow in Computational Biology, Broad Institute of MIT and Harvard Ph.D. in Computational Genomics, Rutgers University B.S. in Biotechnology, Nanjing University, China **Research Focus**: Keywords include Data Science, Computational Biology, Functional Genomics, RNA, Cancer, Inflammation, and Machine Learning. The lab explores regulatory mechanisms underlying disease, with a focus on translational control, cancer metastasis, and inflammatory networks. **Grants & Advising**: No specific grants or student advisees listed. The lab emphasizes collaborative projects and computational-experimental approaches. **Lab Affiliations**: Zhe Ji’s lab is part of Northwestern’s interdisciplinary environment, bridging engineering and medicine to advance genomic technologies and therapeutic strategies.
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Thomas Winkler is an Associate Professor at the Division of Micro and Nanosystems, KTH Royal Institute of Technology, Sweden, and collaborates with TU Braunschweig, Germany. His research focuses on solving life science challenges using microsystems tools, particularly in neuropsychiatric disorders like schizophrenia. He develops organ-on-chip models, engineered microfluidic platforms, and biosensors for point-of-care diagnostics. Winkler leads an interdisciplinary ERC-funded team addressing metabolic coupling in neurovascular units and oxidative stress biomarkers. Key achievements include the ERC Starting Grant (2023) and work on electrochemical sensors for clozapine monitoring. He teaches courses such as Microsystem Technology (EK2350) and supervises PhD and postdoctoral researchers. Current projects include machine learning-guided robotic organoid maturation and electrochemical technology development for the CHIPzophrenia initiative. His lab actively seeks talent through open positions in Stockholm and Braunschweig. Scientific awards include the ERC Starting Grant and Marie Skłodowska-Curie Actions Fellowship. Research spans sensor development, microfabrication, and biomaterials, with a focus on translating lab technologies to clinical applications. Collaborations bridge engineering and life sciences, emphasizing personalized mental healthcare solutions.
Jeffrey Beekman is a Full Professor at the University Medical Center Utrecht, specializing in translational research for chronic diseases through the Department of Pediatric Pulmonology. His work bridges basic and clinical research to develop novel diagnostics and therapeutics for conditions like cystic fibrosis (CF) and Primary Ciliary Dyskinesia. Education: PhD in Molecular Immunology (2004) Key Roles: Principle Investigator since 2010, co-founder of FAIR Therapeutics, Board Member of the Dutch Society for Stem Cell Research His research focuses on patient-derived organoid models to study disease mechanisms, validate therapeutic targets, and optimize drug development. Strategic programs include Child Health and Regenerative Medicine & Stem Cells . Recent publications highlight his work on CFTR gene therapy, organoid-based drug efficacy testing, and host-pathogen interactions in CF. Collaborations span molecular biology, clinical pulmonology, and biotech translation. Key Techniques: Organoid modeling, RNA sequencing, Forskolin-induced swelling assay Diseases Studied: Cystic Fibrosis, Colorectal Cancer Susceptibility, Primary Ciliary Dyskinesia
Kara McKinley is an Assistant Professor of Stem Cell and Regenerative Biology at Harvard University , joining the department in 2021. She is a Principal Faculty member at the Harvard Stem Cell Institute , an Associate member of the Broad Institute of MIT and Harvard , and a Freeman Hrabowski Scholar at the Howard Hughes Medical Institute . Her research focuses on the regenerative capacity of the human uterus , particularly the endometrium, which undergoes ~400 cycles of tissue remodeling, shedding, and repair during the reproductive lifespan. Using rodent models , genetic, molecular, and live microscopy tools, her lab investigates cellular and molecular mechanisms of regeneration, defects leading to diseases like endometriosis, and applications in regenerative medicine . Her work also explores cell division , centromere biology , and CRISPR genome engineering . Current research trends in her publications include epithelial zonation in the small intestine , mechanisms of endometrial regeneration , macropinocytosis in Hydra , and academic mentorship strategies . Her studies span cellular biomechanics , mitotic regulation , and translational approaches for tissue repair. NIH Director’s New Innovator Award (terminated in 2025 litigation with federal government) Freeman Hrabowski Scholar (Broad Institute) Kara mentors Harvard undergraduates, graduate students, and postdoctoral fellows through rotations and research opportunities. Her lab is based at Harvard’s Bauer 306 and advocates for gender equity in life sciences faculty via the Leading Edge initiative. Funding includes a now-terminated NIH New Innovator grant aimed at menstrual health research.
Mahima Swamy is a Principal Investigator and Wellcome Trust Sir Henry Dale Fellow at the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU) at the University of Dundee. Her research focuses on understanding immune interactions at the intestinal epithelium, particularly the role of intraepithelial lymphocytes (IEL) in maintaining gut homeostasis and resisting infections. She leads a lab investigating IEL biology, including their regulation by PIM kinases and LRRK2 in inflammatory bowel diseases (IBD) and Crohn’s disease. Dr. Swamy earned her BSc in Biological Sciences from BITS Pilani and completed her PhD at the Max-Planck Institute in Freiburg, Germany. She held postdoctoral fellowships at CRUK London Research Institute and the University of Dundee before establishing her independent group in 2016. Her work combines proteomics, mouse models, and in vitro co-cultures to explore IEL signaling pathways and their dysregulation in diseases. Key research interests include: IEL-mediated protection against pathogens, metabolic adaptations of IEL to the gut environment, and the role of LRRK2 in intestinal immune function. Her lab collaborates with the Alessi lab to study LRRK2 inhibitors for IBD therapy. Education: BSc (BITS Pilani) → PhD (MPIIB, Germany) → Postdocs (CRUK, Dundee) Lab Members: Includes PhD students (Rebecca Pemberton, Srishti, Neema Skariah) and postdocs (Amanpreet Chawla, Purbasha Bhattacharya) Collaborations: Tayside Immunology Group, Society for Mucosal Immunology Scientific achievements include discoveries of PIM kinases in IEL function and LRRK2’s role in gut inflammation. Her group has pioneered tools like phospho-proteomic analyses and epithelial organoid:IEL co-cultures.
Dr. Rebecca Clark is an Associate Professor in the Department of Biosciences at Durham University. Her research focuses on understanding intestinal function in health and disease using the Drosophila model. She investigates how the intestinal epithelium balances barrier function, nutrient absorption, microbial symbiosis, and cell turnover, particularly during aging and disease states. Key research questions include mechanisms of intestinal barrier failure and the interplay between nutrition and intestinal homeostasis. Her work integrates genetic, microbiological, and physiological approaches to explore aging-related pathologies. Current projects aim to identify molecular pathways linking intestinal health to longevity. Supervised postgraduate students include Ale Acevedo Marcelin, Beñat Yanez, and Fanila Shahzad. Dr. Clark’s lab uses Drosophila as a model system due to its powerful genetic tools and evolutionary relevance. Research has implications for understanding human conditions such as inflammatory bowel disease and age-related metabolic disorders. Recent findings highlight microbiota-independent aging mechanisms and the role of tricellular junctions in stem cell regulation. No scientific awards are explicitly listed in the provided materials. Her research has been published in journals like Cell , Nature Cell Biology , and Proceedings of the National Academy of Sciences .
Professor David Ackerley (Victoria University of Wellington) is a leading microbiologist and enzyme engineer specializing in directed evolution of bacterial enzymes for biotechnological applications. As Biotechnology Programme Director since 2006, he lectures in foundational courses like BTEC101 and BTEC201. Academic rank: Professor of Biotechnology Institutional affiliation: Victoria University of Wellington Research focus areas: Microbial Biotechnology, Drug Discovery, Synthetic Biology His research employs Darwinian evolutionary principles to engineer enzymes with enhanced activities, particularly targeting non-ribosomal peptide synthetases and nitroreductases for antibiotic development and cancer therapy. Recent work explores metagenomic domain substitution in pyoverdine biosynthesis and Purpuramine R from marine sponges. Key publications demonstrate innovations in metagenomic library construction , CRISPR screening for regeneration genes, and structural characterization of engineered enzymes. His team has developed NTR 2.0 , a high-efficacy nitroreductase for targeted cell ablation. Current research projects include: Clean solutions from dirty genes: Plastic-degrading enzyme discovery Engineering enzymes for CAR T-cell-chemotherapy synergy Repurposing niclosamide against Gram-negative superbugs Grants from the Health Research Council of New Zealand, Royal Society of New Zealand, and Cancer Society of NZ support his work. Collaborations span biomedical research, synthetic biology, and environmental applications.
Michael Boutros is a Full Professor at Heidelberg University and Head of Division at the German Cancer Research Center (DKFZ). He currently serves as Dean of the Medical Faculty at Heidelberg University (since 2023) and Director of the Marsilius Kolleg (since 2020). He has held leadership roles including Coordinator of the Functional and Structural Genomics Program at DKFZ (2014–2023) and Acting Scientific Director (2015–2016). His academic base is within the Medical Faculty, focusing on molecular oncology and functional genomics. PhD, Witten/Herdecke University (1993–1996) Postdoctoral Research, Harvard Medical School (1999–2003) MPA, John F. Kennedy School of Government, Harvard University (1999–2001) Additional training: Cold Spring Harbor Laboratory, SUNY Stony Brook His research centers on Wnt signaling, functional genomics, and cancer pathways. He leads major research initiatives such as CRC 1324 on Wnt signaling and the ERC Synergy Grant DECODE. His work integrates high-throughput screening, CRISPR, and systems biology to dissect signaling networks in cancer and development. He has pioneered genome-wide RNAi and CRISPR screens to identify novel regulators of Wnt signaling across models. The 15 most recent articles reflect a strong focus on Wnt pathway regulation using functional genomics in both Drosophila and mammalian systems. Themes include high-throughput screening, CRISPR-based validation, cross-species conservation, and therapeutic targeting. Keywords span Cancer Biology, Systems Biology, and Signal Transduction, with subfields like RNAi, ubiquitination, stem cell regulation, and machine learning in image analysis. Michael Boutros has received numerous scientific honors: Elected member, Leopoldina National Academy of Sciences (2022) Elected member, Heidelberg Academy of Sciences (2022) EMBO Member (2013) ERC Advanced Grant (2012) Johann-Georg Zimmermann Research Award (2007) EMBO Young Investigator (2005) Member, 'Die Junge Akademie' (2003) He has been a recipient of the Emmy-Noether Program, McCloy Fellowship, Boehringer Ingelheim PhD Fellowship, Studienstiftung Fellowship, and Fulbright Fellowship. As a mentor and research leader, he has supervised numerous early-career scientists and coordinated large collaborative grants including the FP7 'CancerPathways' project. He currently serves as Speaker of the Research and Strategy Commission at Heidelberg University and Managing Director of the Health and Life Science Alliance Heidelberg Mannheim. He leads the CRC 1324 on Wnt signaling and is Coordinating PI of the ERC Synergy Grant DECODE. He is also Spokesperson of DFG Research Group 1036 and Coordinator of the former FP7 Coordinated Project 'CancerPathways'. His lab employs cutting-edge functional genomics tools to decode signaling networks in cancer and development.
David Walker is a Professor and Vice Chair of Academic Personnel in the Department of Integrative Biology and Physiology at the University of California, Los Angeles. He leads a research lab focused on understanding the molecular and cellular basis of aging, utilizing Drosophila melanogaster to investigate mechanisms such as mitochondrial dysfunction, autophagy, and intestinal barrier integrity. His work aims to identify therapeutic targets for age-related diseases. Education: B.S., Genetics, Queen's University Belfast (1995) MRes, Molecular Biology, University of Manchester (1996) Ph.D., Genetics, University of Manchester (2000) Walker's research interests center on the biological processes driving aging, with emphasis on mitochondrial dynamics, neurodegeneration, and gut-microbiota interactions. His lab employs genetic, molecular, and physiological approaches in Drosophila to dissect how cellular deterioration impacts lifespan and healthspan, bridging insights to human aging pathologies. Key themes include the role of autophagy adaptors (e.g., p62/SQSTM1), mitochondrial fission, and intestinal homeostasis in longevity. His recent publications (2014–2024) reveal a consistent focus on brain aging, mitophagy, and gut-brain axis disruptions, with trends toward identifying midlife interventions for healthspan extension. Articles frequently integrate cellular stress responses, metabolic regulation, and neurodegeneration, highlighting Drosophila as a versatile model for translational aging research. No scientific awards, prizes, or fellowships are mentioned in the provided text. While specific grants or student advisees are not detailed, Walker's lab actively mentors researchers and contributes to collaborative projects on aging mechanisms. Future directions may involve exploring mitochondrial-immune interactions and novel longevity pathways. Walker directs a Drosophila-focused laboratory at UCLA, emphasizing genetic screens and mechanistic studies to uncover evolutionarily conserved aging pathways. The team investigates tissue-specific aging cascades, including neuronal and intestinal systems, to develop strategies for mitigating age-related decline.
